Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DXCM
Strong BuyPremium GrowerFLAGDexCom, Inc. · Healthcare · United States · $34.3B · Avg Vol: $413M/d
DexCom has strong quality at Q81 and momentum M73, but value at V32 is well below the calibrated floor, so stage one fails. Insider selling is separately adverse.
COMPANY DESCRIPTION
DexCom, Inc. develops, manufactures, and markets innovative continuous glucose monitoring (CGM) systems for people with diabetes. The company is a market leader in real-time CGM technology, offering advanced, highly accurate, and user-friendly devices that significantly improve diabetes management. DexCom is expanding market access and enhancing its technology to serve a growing global diabetic population.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9B | 3.6B | 4.0B | 4.7B | 17.0% | 5.0B | 5.2B | 5.8B | 11.5% |
| EPS | 0.88 | 1.40 | 1.46 | 2.14 | 34.5% | 2.53 | 2.73 | 3.20 | 22.3% |
| Shares | 386.3M | 385.4M | 390.7M | 384.8M | -0.4% | 377.4M | — | — | — |
| Debt | 2.1B | 2.6B | 2.6B | 1.4B | -13.5% | 1.4B | — | — | — |
| Equity | 2.1B | 2.1B | 2.1B | 2.7B | 8.8% | — | — | — | — |
| Op CF | 669.5M | 748.5M | 989.5M | 1.4B | 29.1% | 1.7B | — | — | — |
| Inv CF | -521.5M | -507.2M | -207.5M | 536.0M | — | — | — | — | — |
| Fin CF | -552.5M | -318.6M | -734.8M | -1.7B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DXCM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DXCM | DexCom, Inc.(you) | $34.3B | 83 | Strong Buy |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.2B | 83 | Strong Buy |
| STE | STERIS plc | $22.8B | 76 | Buy |
| GEHC | GE HealthCare Technologies Inc. | $32.4B | 63 | Hold |
| EW | Edwards Lifesciences Corporation | $52.0B | 64 | Hold |
| GMED | Globus Medical, Inc. | $11.1B | 92 | Strong Buy |
| BIO-B | Bio-Rad Laboratories, Inc. | $8.3B | 78 | Buy |
| HAE | Haemonetics Corporation | $4.7B | 86 | Strong Buy |
| BSX | Boston Scientific Corporation | $67.9B | 48 | Hold |
| SYK | Stryker Corporation | $126.8B | 57 | Hold |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%